Novel therapeutic pathways for amyotrophic lateral sclerosis (ALS): leveraging the NOX route.

Font Standard Bold
Login

Project search
Actual Project
Recent projects
Graphics
Login

Research unit

INNOSUISSE

Project number

9958.1;7 PFLS-LS

Project title

Novel therapeutic pathways for amyotrophic lateral sclerosis (ALS): leveraging the NOX route.

Basic data
Texts
Participants

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	Novel therapeutic pathways for amyotrophic lateral sclerosis (ALS): leveraging the NOX route.
Abstract (English)	UNIGE proposes to test GKT-generated proprietary NOX inhibitors in in vitro and in vivo models of amyotrophic lateral sclerosis (ALS). ALS is an incurable orphan disease, which potentially allows rapid entry of GKT inhibitors into clinical trials. Because chronic NOX inhibition might lead to immunosuppression, such possible adverse effect of GKT inhibitors will also be evaluated. This is a scientifically challenging project requiring collaboration between GKT and the academic laboratory. The project will add value through opening the CNS field for GKT.

Category

Text

Short description
(English)

Novel therapeutic pathways for amyotrophic lateral sclerosis (ALS): leveraging the NOX route.

Abstract
(English)

UNIGE proposes to test GKT-generated proprietary NOX inhibitors in in vitro and in vivo models of amyotrophic lateral sclerosis (ALS). ALS is an incurable orphan disease, which potentially allows rapid entry of GKT inhibitors into clinical trials. Because chronic NOX inhibition might lead to immunosuppression, such possible adverse effect of GKT inhibitors will also be evaluated. This is a scientifically challenging project requiring collaboration between GKT and the academic laboratory. The project will add value through opening the CNS field for GKT.